Shares of Bruker Co. (NASDAQ:BRKR) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $44.67.
Several equities research analysts recently weighed in on the company. BidaskClub raised Bruker from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Zacks Investment Research cut Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Svb Leerink raised Bruker from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $40.00 to $53.00 in a research note on Friday, May 3rd. Leerink Swann raised Bruker from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, UBS Group raised Bruker from a “sell” rating to a “neutral” rating and set a $43.00 target price on the stock in a research note on Friday, May 3rd.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC purchased a new stake in shares of Bruker in the first quarter worth $35,000. NumerixS Investment Technologies Inc grew its stake in shares of Bruker by 150.0% in the first quarter. NumerixS Investment Technologies Inc now owns 1,000 shares of the medical research company’s stock worth $38,000 after acquiring an additional 600 shares during the last quarter. Hanseatic Management Services Inc. grew its stake in shares of Bruker by 52.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock worth $50,000 after acquiring an additional 579 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Bruker in the first quarter worth $67,000. Finally, Captrust Financial Advisors grew its stake in shares of Bruker by 164.7% in the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock worth $54,000 after acquiring an additional 1,135 shares during the last quarter. 69.33% of the stock is currently owned by hedge funds and other institutional investors.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.04. The company had revenue of $461.40 million for the quarter, compared to analysts’ expectations of $450.46 million. Bruker had a return on equity of 26.28% and a net margin of 9.53%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.24 earnings per share. As a group, equities analysts anticipate that Bruker will post 1.61 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 21st. Stockholders of record on Monday, June 3rd will be paid a $0.04 dividend. The ex-dividend date of this dividend is Friday, May 31st. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.38%. Bruker’s dividend payout ratio is currently 11.43%.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: What is Blockchain?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.